Clinical Research Papers:
Percutaneous computed tomographyguided cryoablation for recurrent retroperitoneal soft tissue sarcoma: a study of safety and efficacy
PDF | Full Text | How to cite
Metrics: PDF 2085 views | Full Text 3275 views
Wenzhe Fan1, Lizhi Niu2,3, Yu Wang1, Yingqiang Zhang1, Xuehua Yao1, Guosheng Tan4, Jianyong Yang4,5, Jiaping Li1
1Department of Interventional Oncology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China
2Fuda Cancer Hospital, Guangzhou, China
3Fuda Institute of Cryosurgery for Cancer, Guangzhou, China
4Department of Interventional Radiology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China
5Department of Medical Imaging, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China
Correspondence to:
Jia-Ping Li, email: [email protected]
Keywords: computer tomography, cryoablation, retroperitoneal sarcoma, survival, response rate
Received: October 10, 2015 Accepted: April 16, 2016 Published: May 19, 2016
ABSTRACT
Aims: To evaluate the use of computed tomography image-guided percutaneous cryoablation for recurrent retroperitoneal soft tissue sarcomas (RPSs).
Results: Adverse events were limited to grades 1 and 2, included fever (n = 19), local pain (n = 11), emesis (n = 10), frostbite (n = 6), and nerve injury (n = 1). Fever was more frequent in the large tumor group (15.8%) than in small tumor group (1.9%) (P = 0.008). Median PFS and OS were 37.0 ± 7.7 months (range, 4–39 months) and 43.0 ± 5.9 months (range, 6–54 months), respectively. PFS and OS were significantly longer in the small tumor group than in the large tumor group (P = 0.011 and P = 0.015, respectively), but the response rate (82.7% vs. 72.8%, P = 0.240) did not differ significantly. On univariate analysis, tumor size, tumor invasion grade, and distant metastasis were significant prognostic factors for PFS and OS. On multivariate analysis, a tumor size ≥10 cm was an independent negative prognostic factor for PFS and OS after cryoablation (HR: 3.98, 95% CI: 1.27–12.50, P = 0.018 and HR: 4.33, 95% CI: 1.41–13.26, P = 0.010, respectively).
Materials and Methods: Data from 72 patients with recurrent RPSs who underwent percutaneous cryoablation were reviewed retrospectively. The prognostic factors for progression-free survival (PFS), overall survival (OS), and efficacy based on mRECIST criteria were analysis. Adverse events were compared according to tumor size (<10 and ≥10 cm).
Conclusion: Minimally invasive percutaneous cryoablation was safe and efficacious for recurrent RPSs.